Effects of fremanezumab on migraine-associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double-blind, placebo-controlled trial.
Muneto TatsumotoMiki IshidaKatsuhiro IbaByung-Kun KimXiaoping NingChihiro OsawaMasami NakaiYuka KuritaPublished in: Headache (2024)
Monthly and quarterly administered fremanezumab effectively prevented EM in Japanese and Korean patients. Fremanezumab also improved other disease aspects including the need for acute headache medications and the frequency of migraine-associated symptoms.
Keyphrases
- double blind
- placebo controlled
- clinical trial
- end stage renal disease
- phase iii
- newly diagnosed
- phase ii
- ejection fraction
- chronic kidney disease
- prognostic factors
- study protocol
- liver failure
- open label
- randomized controlled trial
- peritoneal dialysis
- sleep quality
- drug induced
- depressive symptoms
- patient reported outcomes
- patient reported
- aortic dissection